News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
March, 2025
March 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Emir Sokolović: The need for systematic thyroid monitoring in mNSCLC patients on ICIs
Emir Sokolović/cancer.eu
Mar 27, 2025, 10:49

Emir Sokolović: The need for systematic thyroid monitoring in mNSCLC patients on ICIs

Emir Sokolović, Medical Oncology Resident at Clinical Center University of Sarajevo, shared a post on LinkedIn about a paper he co-authored with colleagues published in Biomolecules and Biomedicine:

“Thyroid dysfunction is a common immune-related adverse event in patients with metastatic NSCLC receiving ICIs – particularly atezolizumab – and may correlate with improved PFS.

These observations highlight the importance of systematic thyroid monitoring in this population and raise the possibility that thyroid dysfunction could serve as a surrogate marker of enhanced immunotherapy efficacy.

Further prospective research is needed to clarify the underlying mechanisms and confirm the potential prognostic value of this endocrine irAE.”

“Impact of thyroid immune-related adverse events on clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with checkpoint inhibitor therapy: A single center study”

Authors: Šejla Cerić, Timur Cerić, Emir Sokolović, Jasmina Dalač, Dragana Miletić, Inga Marijanović, Layan Mattar, Amina Aljić, Selma Agić-Bilalagić, Amera Šadija, Miran Hadžiahmetović, Semir Bešlija.

Emir Sokolović: The need for systematic thyroid monitoring in mNSCLC patients on ICIs

More posts featuring Emir Sokolović.

Amera Šadija Amina Aljic atezolizumab Biomolecules and Biomedicine cancer Dragana Miletić Emir Sokolović ICIs Inga Marijanović Jasmina Dalač Layan Mattar metastatic NSCLC Miran Hadžiahmetović NSCLC OncoDaily Oncology Sejla Ceric Selma Agić-Bilalagić Semir Beslija Thyroid dysfunction Timur Cerić
Special Coverage
Blog
Mar 30, 2025, 18:26
Indiana’s first mobile lung screening program is officially on the road - IU Simon Comprehensive Cancer Center
Blog
Mar 30, 2025, 18:14
Join the Richard and Alice Bucher Emerald Circle and help create a world without pediatric cancers - St. Baldrick's Foundation
Blog
Mar 30, 2025, 18:01
Philippe Spiess: Always an honor to deliver an update in the management of bladder cancer with Tom Flaig
Blog
Mar 30, 2025, 17:46
Thought-provoking trial on localized pancreatic cancer presented by Ethan Agritelley at SSO2025 - Duke Surgical Oncology
Blog
Mar 30, 2025, 17:44
Addressing Gaps in Awareness, Care, and Support for the Early-Age Onset Digestive Cancer Community - European Cancer Organisation
Blog
Mar 30, 2025, 17:34
Olga Kantor: Fantastic presentation by Monika Masanam on MIBC after NST at SSO2025
Blog
Mar 30, 2025, 17:19
Carlos Ayala-Navarro on the immune microenvironment in appendiceal cancers - Moffitt Cancer Center
Blog
Mar 30, 2025, 17:19
Roupen Odabashian: Comparing Research Compensation - Healthcare vs AI
Blog
Mar 30, 2025, 17:05
Julien Mazieres: Heterogeneity of resistance mechanisms should lead to a personalized strategy
Blog
Mar 30, 2025, 16:56
Joe Chang: Optimal first-line treatment for EGFR-mutated mNSCLC
Positive
Mar 30, 2025, 16:44
Yüksel Ürün: FDA approves neoadjuvant and adjuvant durvalumab in MIBC
Blog
Mar 30, 2025, 16:43
Highlights from SSO25